U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Mantle Cell Lymphoma

MedGen UID:
208958
•Concept ID:
C0855138
•
Neoplastic Process
Synonym: Mantle Cell Lymphoma Refractory

Definition

Mantle cell lymphoma resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Mantle Cell Lymphoma

Professional guidelines

PubMed

Management of relapsed/refractory mantle cell lymphoma.
Alzahrani M, Villa D
Leuk Lymphoma 2024 Aug;65(8):1044-1054. Epub 2024 Apr 18 doi: 10.1080/10428194.2024.2338851. PMID: 38635491
Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.
Al-Mansour M
Clin Lymphoma Myeloma Leuk 2022 Nov;22(11):e1019-e1031. Epub 2022 Aug 3 doi: 10.1016/j.clml.2022.07.017. PMID: 36068158
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
Dreyling M, Aurer I, Cortelazzo S, Hermine O, Hess G, Jerkeman M, Le Gouill S, Ribrag V, Trněný M, Visco C, Walewski J, Zaja F, Zinzani PL
Leuk Lymphoma 2018 Aug;59(8):1814-1828. Epub 2017 Nov 27 doi: 10.1080/10428194.2017.1403602. PMID: 29172868

Recent clinical studies

Etiology

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Diseases and Injuries Collaborators
Lancet 2024 May 18;403(10440):2133-2161. Epub 2024 Apr 17 doi: 10.1016/S0140-6736(24)00757-8. PMID: 38642570Free PMC Article
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD
J Clin Oncol 2023 May 10;41(14):2594-2606. Epub 2023 Feb 8 doi: 10.1200/JCO.22.01797. PMID: 36753699Free PMC Article
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM
J Clin Oncol 2023 Jan 20;41(3):555-567. Epub 2022 Jun 4 doi: 10.1200/JCO.21.02370. PMID: 35658525Free PMC Article
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W
Lancet 2018 Feb 17;391(10121):659-667. Epub 2017 Dec 11 doi: 10.1016/S0140-6736(17)33108-2. PMID: 29241979Free PMC Article
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA
N Engl J Med 2013 Aug 8;369(6):507-16. Epub 2013 Jun 19 doi: 10.1056/NEJMoa1306220. PMID: 23782157Free PMC Article

Diagnosis

Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M, Gonzalez T, Ivanov S, Sandoval-Sus J
Curr Oncol Rep 2022 Oct;24(10):1313-1326. Epub 2022 May 31 doi: 10.1007/s11912-022-01297-x. PMID: 35639332
Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre TA, Cheah CY, Wang ML
Blood 2022 Feb 3;139(5):666-677. doi: 10.1182/blood.2021013326. PMID: 34679161Free PMC Article
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L
Am J Clin Dermatol 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. PMID: 32613545
IMiDs New and Old.
Yamshon S, Ruan J
Curr Hematol Malig Rep 2019 Oct;14(5):414-425. doi: 10.1007/s11899-019-00536-6. PMID: 31302872
Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E, Atilla PA, Demirer T
Int J Hematol 2017 Mar;105(3):257-264. Epub 2016 Dec 19 doi: 10.1007/s12185-016-2164-2. PMID: 27995456

Therapy

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM
J Clin Oncol 2023 Jan 20;41(3):555-567. Epub 2022 Jun 4 doi: 10.1200/JCO.21.02370. PMID: 35658525Free PMC Article
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Guo H, Zhou L, Huang J, Novotny W, Kim P, Yu Y, Wu B, Zhu J
Blood 2022 May 26;139(21):3148-3158. doi: 10.1182/blood.2021014162. PMID: 35303070Free PMC Article
Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre TA, Cheah CY, Wang ML
Blood 2022 Feb 3;139(5):666-677. doi: 10.1182/blood.2021013326. PMID: 34679161Free PMC Article
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L
Am J Clin Dermatol 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. PMID: 32613545
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM
N Engl J Med 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347. PMID: 32242358Free PMC Article

Prognosis

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Diseases and Injuries Collaborators
Lancet 2024 May 18;403(10440):2133-2161. Epub 2024 Apr 17 doi: 10.1016/S0140-6736(24)00757-8. PMID: 38642570Free PMC Article
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM
J Clin Oncol 2023 Jan 20;41(3):555-567. Epub 2022 Jun 4 doi: 10.1200/JCO.21.02370. PMID: 35658525Free PMC Article
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L
Am J Clin Dermatol 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. PMID: 32613545
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM
N Engl J Med 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347. PMID: 32242358Free PMC Article
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA
N Engl J Med 2013 Aug 8;369(6):507-16. Epub 2013 Jun 19 doi: 10.1056/NEJMoa1306220. PMID: 23782157Free PMC Article

Clinical prediction guides

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Causes of Death Collaborators
Lancet 2024 May 18;403(10440):2100-2132. Epub 2024 Apr 3 doi: 10.1016/S0140-6736(24)00367-2. PMID: 38582094Free PMC Article
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Minson A, Hamad N, Cheah CY, Tam C, Blombery P, Westerman D, Ritchie D, Morgan H, Holzwart N, Lade S, Anderson MA, Khot A, Seymour JF, Robertson M, Caldwell I, Ryland G, Saghebi J, Sabahi Z, Xie J, Koldej R, Dickinson M
Blood 2024 Feb 22;143(8):673-684. doi: 10.1182/blood.2023021306. PMID: 37883795
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM
J Clin Oncol 2023 Jan 20;41(3):555-567. Epub 2022 Jun 4 doi: 10.1200/JCO.21.02370. PMID: 35658525Free PMC Article
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu KL, Bishton M, Collins GP, Eliadis P, Peyrade F, Lee Y, Eckert K, Neuenburg JK, Tam CS
J Hematol Oncol 2021 Oct 30;14(1):179. doi: 10.1186/s13045-021-01188-x. PMID: 34717692Free PMC Article
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA
N Engl J Med 2013 Aug 8;369(6):507-16. Epub 2013 Jun 19 doi: 10.1056/NEJMoa1306220. PMID: 23782157Free PMC Article

Recent systematic reviews

Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C, Kabadi SM, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z
Clin Ther 2019 Nov;41(11):2357-2379.e1. Epub 2019 Nov 4 doi: 10.1016/j.clinthera.2019.09.012. PMID: 31699438
A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma.
Parrott M, Rule S, Kelleher M, Wilson J
Clin Lymphoma Myeloma Leuk 2018 Jan;18(1):13-25.e6. Epub 2017 Oct 13 doi: 10.1016/j.clml.2017.10.004. PMID: 29122536
Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review.
Njue A, Colosia A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F
Clin Lymphoma Myeloma Leuk 2015 Jan;15(1):1-12.e7. Epub 2014 Jun 11 doi: 10.1016/j.clml.2014.03.006. PMID: 25052050

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...